Journal
JOURNAL OF CROHNS & COLITIS
Volume 15, Issue 8, Pages 1376-1386Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ecco-jcc/jjab046
Keywords
Vaccination strategies; inflammatory bowel disease; SARS-CoV-2; immunogenicity
Categories
Funding
- Leona M. and Harry B. Helmsley Charitable Trust
- Siemens
Ask authors/readers for more resources
Patients with inflammatory bowel diseases (IBD) have been considered high-risk for COVID-19 infection and complications since the start of the pandemic. However, they were excluded from clinical phase III vaccine trials, leading to challenges in assessing the effectiveness of new vaccines. Adapted vaccination strategies may be needed for some IBD patients to optimize immune response. Therefore, further research is needed to develop tailored vaccination plans for IBD patients.
Since the beginning of the pandemic, patients with inflammatory bowel diseases [IBD] have been considered at high risk for infection and complications of COVID-19. IBD patients and patients taking immunosuppressive therapy were excluded from clinical phase III vaccine trials, complicating the assessment of effectiveness of these new vaccines. From past experience we know that adapted vaccination strategies may be appropriate in some IBD patients to optimise immunogenicity. We review current evidence on SARS-CoV-2 vaccination relevant to IBD patients, including immune responses from humoral to cellular, emerging data on new variants, and off-label vaccination schemes. We also identify clinical and scientific knowledge gaps that can be translated into both large-scale population-based studies and targeted vaccine studies to describe the precise immune responses induced by SARS-CoV-2 vaccines in IBD patients. We strongly endorse the recommendation of vaccinating IBD patients to ensure maximal protection from COVID-19 both for the individual and the community.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available